Jillanne Schulte Wall, ASHP Senior Director, Health & Regulatory Policy and Mary Ann Kliethermes, ASHP Director, Medication Safety & Quality, discuss CMS’s recent telehealth changes, the resulting regulatory flexibilities that are helpful to our members and their patients, and ASHP’s next steps on telehealth advocacy.
SPEAKERS
Mary Ann Kliethermes received a BS in pharmacy from the University of Michigan in 1977 her Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science in 1981. Her career includes clinical practice and management in hospital, home infusion, ambulatory practice and academia. Her current position is Director of Medication Safety and Quality at the American Society of Health-System Pharmacists. Her expertise is in pharmacist reimbursement, medication optimization, safety and quality attainment associated pharmacist services; particularly in new health care models and value-based payment systems.
She has served as Chair of the Section of Ambulatory Care for ASHP , represented ASHP at the Joint Commission Ambulatory Professional and Technical Advisory Group, the Care Transitions Work Group of the PCPI and the Ambulatory Patient Safety Technical Advisory Panel for ASPE/HHS. She is a member of the ASHP SAG on Clinical Practice Advancement. Mary Ann has contributed to the Pharmacy Quality Alliance (PQA) since its inception. She has served as Chair, Executive Committee and Board member of PQA. She is past chair for the APhA PCMH/ACO SIG. Mary Ann has been awarded Pharmacist of the Year, Shining Star Award and the Amy Lodolce Mentorship Award from ICHP, the Distinguished Service Award and Distinguished Leadership in Health-System Pharmacy Practice from ASHP, CCP Outstanding Faculty Award and the Daniel B. Smith Practice Excellence award from APhA.
Jillanne Schulte Wall is the Senior Director of Health & Regulatory Policy for the American Society of Health-System Pharmacists (ASHP) in Bethesda, MD. She serves as ASHP’s primary liaison to federal regulatory agencies and, in conjunction with other members of the Government Relations team, develops and communicates of ASHP’s positions on federal and state laws, regulations, and guidance related to the profession of pharmacy. Additionally, Jillanne works closely with stakeholders in pharmacy, medicine, manufacturing, and patient advocacy on legislative and regulatory issues of importance to ASHP members. Prior to joining ASHP, Jillanne was the Director of Regulatory Affairs for the American Pharmacists Association in Washington, D.C. She began her career as a healthcare attorney at Feldesman Tucker Leifer Fidell LLP in Washington, DC, where she advised healthcare clients on corporate, regulatory, and transactional issues, with a particular emphasis on optimizing performance after the implementation of the Affordable Care Act.